Despite declining headline revenue, the company is executing on commercial growth with strong product sales momentum and expanded market access. The significant cash raise supports ongoing global Phase III trials. Traders should monitor NRDL inclusion prospects for Lisaftoclax in 2026 as a potential catalyst.
Price Chart
Executive Summary
Ascentage Pharma reported unaudited 2025 financial results showing a 41.5% year-over-year decline in total revenue to $82.1 million, driven by the absence of $92.9 million in prior-year intellectual property revenue. However, product sales grew strongly, with Olverembatinib up 80.6% to $62.2 million and Lisaftoclax contributing $10.1 million in its first five months post-launch. The company expanded its clinical pipeline and ended 2025 with $353.2 million in cash, up 95.9% from 2024.
Key Financial Metrics
Key Facts
- Total revenue declined 41.5% YoY to $82.1 million in 2025, primarily due to absence of $92.9 million in IP revenue from 2024
- Olverembatinib product sales increased 80.6% YoY to $62.2 million
- Lisaftoclax launched in July 2025; generated $10.1 million in sales over five months
- R&D expenses rose 20.1% to $162.7 million; selling and distribution costs up 80.4% to $50.6 million
- Net loss widened to $177.7 million from $55.6 million in 2024
- Cash and bank balances increased 95.9% to $353.2 million, driven by $322.6 million in net IPO and follow-on offering proceeds
Financial Impact
Revenue down $52.2 million YoY, but core product sales up $39.3 million; cash position increased by $180.4 million from equity offerings
Risk Factors
- Widening net loss despite revenue growth from products
- Heavy reliance on future clinical and regulatory success of late-stage pipeline
- Currency fluctuations due to international operations and reporting in USD
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3262673 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 3d ago | 6-K | $14.92 | awaiting T+1 | — | $15.61 (+4.66%) |
Oct 21, 2026 4d ago | 6-K | $14.92 $15.44 | ▲ +3.49% | ▲ +4.01% | $15.61 (+4.66%) |
Oct 15, 2026 11d ago | 6-K | $14.69 $15.37 | ▲ +4.63% | ▲ +5.74% | $15.61 (+6.30%) |
Sep 17, 2026 5w ago | 6-K | $15.37 $15.06 | ▲ +2.02% | ▲ +1.90% | $15.61 (−1.59%) |
Aug 19, 2026 9w ago | Press Release | $17.32 $17.00 | ▲ +1.85% | ▲ +2.26% | $15.61 (+9.84%) |
Aug 5, 2026 11w ago | 6-K | $16.86 $17.09 | ▲ +1.39% | ▲ +1.55% | $15.61 (−7.36%) |
Aug 3, 2026 12w ago | 6-K | $16.81 $16.69 | ▼ −0.68% | ▼ −2.49% | $15.61 (−7.08%) |
Jul 26, 2026 13w ago | Press Release | $18.89 $18.29 | ▼ −3.20% | ▼ −3.44% | $15.61 (−17.34%) |
Jul 20, 2026 14w ago | 6-K | $18.37 $19.10 | ▲ +3.97% | ▲ +3.14% | $15.61 (−15.00%) |
Jul 13, 2026 14w ago | 6-K | $19.24 $20.18 | ▲ +4.89% | ▲ +4.49% | $15.61 (−18.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers